Medical Microbiology Testing Technology Market Report 2026

The medical microbiology testing technology market size has grown strongly in recent years. It will grow from $6.0 billion in 2025 to $6.5 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing incidence of infectious diseases, growing antimicrobial resistance awareness, rising healthcare expenditure, expansion of clinical laboratories, increasing adoption of automated systems.

The medical microbiology testing technology market size is expected to see strong growth in the next few years. It will grow to $8.82 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to rising demand for rapid and point-of-care testing, growing government initiatives and public health programs, increasing focus on food and pharmaceutical safety testing, expansion in emerging markets, rising integration of laboratory information systems. Major trends in the forecast period include advancements in molecular diagnostics, innovations in high-throughput testing platforms, developments in multiplex and rapid diagnostic tests, increasing research and development in microbiology, technological integration with serological and immunological testing.

The increasing demand for rapid pathogen detection and identification is expected to drive the growth of the medical microbiology testing technology market in the coming years. Rapid pathogen detection and identification involve the use of diagnostic technologies that quickly and accurately identify microorganisms such as bacteria, viruses, and other pathogens directly from clinical samples without prolonged culture processes, thereby reducing time to diagnosis and enabling faster clinical decision-making. The demand for rapid detection is rising as public health systems and clinical laboratories worldwide seek to improve turnaround times and respond more effectively to infectious disease outbreaks and growing antimicrobial resistance challenges. Medical microbiology testing technology supports rapid pathogen detection by enabling the swift and accurate identification of infectious agents through advanced diagnostic approaches, helping ensure timely treatment and limit the spread of infections. For example, in November 2025, according to the Infectious Disease Surveillance Center, a Japan-based public health organization, data from April 2025 showed that between 2,104 and 2,153 respiratory pathogen tests were performed per pathogen category during a single reporting period, with positivity rates for severe acute respiratory syndrome coronavirus 2, influenza, respiratory syncytial virus, and parainfluenza ranging from 5.7% to 11.5%. Therefore, the growing demand for rapid pathogen detection and identification is contributing to the expansion of the medical microbiology testing technology market.

Major companies operating in the medical microbiology testing technology market are concentrating on the development of advanced molecular analysis solutions, such as digital PCR (dPCR) assays, to improve research efficiency, increase detection accuracy, and strengthen public health surveillance. Digital PCR assays are highly sensitive technologies capable of detecting and precisely quantifying specific DNA sequences, even at extremely low concentrations, thereby enabling accurate pathogen identification and monitoring. For example, in June 2024, QIAGEN N.V., a Netherlands-based provider of molecular biology and life sciences solutions, introduced 35 new wet-lab validated digital PCR Microbial DNA Detection Assays for its QIAcuity digital PCR platform. These assays are accessible through QIAGEN’s GeneGlobe research platform and are designed to target a broad spectrum of pathogens responsible for tropical diseases such as dengue, chikungunya, and malaria, as well as sexually transmitted infections (STIs) and urinary tract infections (UTIs).

In June 2025, bioMérieux S.A., a France-based provider of in vitro diagnostics solutions, acquired Day Zero Diagnostics for approximately $25 million. Through this acquisition, bioMérieux sought to enhance its next-generation sequencing (NGS) capabilities and expand its rapid diagnostics portfolio to more effectively address antibiotic-resistant infections and improve the management of life-threatening infectious diseases. Day Zero Diagnostics is a US-based diagnostic company developing sequencing-based microbiology testing technology that enables rapid identification of pathogens and antimicrobial resistance profiles directly from clinical samples.

Major companies operating in the medical microbiology testing technology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, Becton Dickinson and Company, bioMérieux SA, Hologic Inc., Sysmex Corporation, Bruker Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Abbott Laboratories, Meridian Bioscience Inc., Fujirebio Diagnostics Inc., Seegene Inc., Oxford Nanopore Technologies plc, Molbio Diagnostics Pvt. Ltd., Hardy Diagnostics, HiMedia Laboratories Pvt. Ltd., Accelerate Diagnostics Inc., Liofilchem S.r.l.

North America was the largest region in the medical microbiology testing technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical microbiology testing technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical microbiology testing technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the medical microbiology testing technology market by increasing costs of imported reagents, analytical instruments, optical components, and electronic modules used in laboratory testing systems. diagnostic laboratories and hospitals in north america and europe are most affected due to dependence on imported equipment, while asia-pacific faces higher production costs for exported instruments. these tariffs are raising operational expenses and slowing laboratory upgrades. at the same time, they are supporting domestic manufacturing of reagents, local instrument assembly, and regional supply chain strengthening.

Medical microbiology testing technology refers to the application of specialized laboratory methods and instruments used to detect, identify, and analyze microorganisms such as bacteria, viruses, fungi, and parasites. It involves examining clinical samples to understand microbial characteristics, behavior, and interactions. This technology supports accurate diagnosis and monitoring of infectious diseases by providing precise and reliable testing results.

The primary product types of medical microbiology testing technology include reagents, instruments, consumables, software, and services. Reagents are chemical or biological substances used to detect or quantify microorganisms such as bacteria, viruses, fungi, and parasites using culture methods, PCR, immunoassays, and DNA sequencing. Technologies include cell culture, microscopy, and serology. Applications include infectious disease diagnostics, non-infectious disease testing, R&D, and clinical trials, serving hospitals, diagnostic labs, pharmaceutical companies, research institutes, and the food and beverage industry.

The medical microbiology testing technology market consists of revenues earned by entities by providing services such as clinical diagnostics, pathogen identification, antimicrobial susceptibility testing, molecular and genetic testing, infection monitoring, outbreak investigation, and laboratory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The medical microbiology testing technology market also includes sales of microbiology analyzers, culture media, reagents and kits, automated identification systems, diagnostic instruments, laboratory consumables, and molecular testing equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.